A retrospective analysis of the effect of patient-specific factors on voriconazole concentrations in oncology patients

Journal of Oncology Pharmacy Practice

Volumn 18, Issue 1, 2012, Pages 3-9

  Lombardi, Lindsey R ^a   Miano, Todd A ^b   Davis, Jennifer L ^b   Morgan, Steven C ^b   Goldstein, Steven C ^b   Vardhanabhuti, Saran ^b   Mitra, Nandita ^c   Vozniak, J Michael ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Child Pugh score; oncology; pharmacokinetics; Voriconazole

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; VORICONAZOLE;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PATIENT; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EXPOSURE; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM;

ADULT; AGE FACTORS; AGED; ALKALINE PHOSPHATASE; ANTIFUNGAL AGENTS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOSES; NEOPLASMS; PYRIMIDINES; RETROSPECTIVE STUDIES; TRIAZOLES; YOUNG ADULT;

EID: 84857976637     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155210397963     Document Type: Article

References (22)

1. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002 ; 347: 408-415 (Pubitemid 34851833)
2. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006 ; 45: 649-663 (Pubitemid 43990568)
3. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003 ; 31: 540-547 (Pubitemid 36444162)
4. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2005 ; 35: 509-513 (Pubitemid 40403355)
5. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007 ; 109: 1532-1535 (Pubitemid 46595688)
6. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008 ; 46: 201-211 (Pubitemid 351269158)
7. Food and Drug Administration. 'Briefing Document for Voriconazole', http://www.fda.gov/ohrms/DOCKETS/ac/01/briefing/3792b2-01-Pfizer.pdf (October 2001, accessed July 1, 2009).
8. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW. Adverse reactions to voriconazole. Clin Infect Dis. 2004 ; 39: 1241-1244 (Pubitemid 40169325)
9. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006 ; 46: 235-243 (Pubitemid 43146453)
10. Roerig, Division of Pfizer. Vfend (voriconazole) package insert. New York, NY, 2008.
11. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007 ; 40: 451-456 (Pubitemid 47288224)
12. Smith J, Safdar N, Knasinski V. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006 ; 50: 1570-1572
13. Purkins L, Wood N, Greenhalgh K, et al. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol. 2003 ; 56: 10-16 (Pubitemid 37491728)
14. Murayama N, Imai N, Nakane T, Shimizu M, Yamazaki H. Roles of CYP3A4 and CYP 2C19 in methylhydroxylated and N-oxidized metabolite formation from voriconazole, a new antifungal agent, in human liver microsomes. Biochemical Pharmacol. 2007 ; 73: 2020-2026 (Pubitemid 46677908)
15. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 status. Clin Pharmacol Ther. 2004 ; 75: 587-588 (Pubitemid 38746611)
16. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009 ; 53: 24-34
17. Wang G, Lei HP, Li Z, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol. 2009 ; 65: 281-285
18. Johnson HJ, Han K, Capitano B, et al. Voriconazole in liver transplant recipients. Antimicrob Agents Chemother. 2010 ; 54: 852-859
19. Amigues I, Cohen N, Chung D, et al. Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010 ; 16: 46-52
20. Lutsar I, Hodges MR, Tomaszewski K, Troke PF, Wood N. Safety of voriconazole and dose individualization. Clin Infect Dis. 2003 ; 36: 1087-1088
21. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008 ; 64: 1147-1161
22. Weiler S, Zoller H, Graziadei I, et al. Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis. Antimicrob Agents Chemother. 2007 ; 51: 3459-3460 (Pubitemid 350067581)